Gilead hit with FDA clinical hold for batch of HIV trials
Pharmaceutical Technology
JUNE 11, 2025
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%
52 
Let's personalize your content